Bosutinib
Brand name: Bosulif
Rank #272 of 500 drugs by total cost
$44.9M
Total Cost
2,962
Total Claims
$44.9M
Total Cost
194
Prescribers
$15K
Cost per Claim
0
Beneficiaries
2,972
30-Day Fills
$231K
Avg Cost/Provider
15
Avg Claims/Provider
About Bosutinib
Bosutinib (sold as Bosulif) was prescribed 2,962 times by 194 Medicare Part D providers in 2023, costing the program $44.9M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 269 | Ipratropium Bromide (Ipratropium Bromide) | $45.4M | 656,249 |
| 270 | Amantadine Hcl (Amantadine) | $45.2M | 173,840 |
| 271 | Insulin Nph Human Isophane (Humulin N) | $44.9M | 172,714 |
| 272 | Bosutinib (Bosulif) | $44.9M | 2,962 |
| 273 | Tramadol Hcl (Tramadol Hcl) | $44.9M | 5,226,406 |
| 274 | Finasteride (Finasteride) | $44.6M | 2,766,115 |
| 275 | Baclofen (Baclofen) | $44.2M | 1,916,226 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology